Pulmonary arterial hypertension: sex-specific differences and outcomes
Therapeutic Advances in Respiratory Disease · 2025-01 · 19
DOI: 10.1177/17534666251350493 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Therapeutic Advances in Respiratory Disease, online erschienen am 20.06.2025. Verfasst von Noura Alturaif und 2 weiteren Autor:innen. Beteiligte Einrichtung: Lung Health Department, Organ Transplant Center, King Faisal Specialist Hospital and Research Centre, Almaather, Riyadh 12713, Saudi Arabia. Hauptthemen laut MEDLINE: Pulmonary Arterial Hypertension, Pulmonary Artery, Health Status Disparities, Arterial Pressure. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Pulmonary arterial hypertension (PAH) is a progressive and life-threatening vascular disease characterized by increased pulmonary vascular resistance, leading to right ventricular failure and death. It has a higher prevalence in women than men, yet notable sex-based differences influence disease presentation, treatment response, and outcomes. This narrative review explores the distinct sex differences in PAH and their significant impact on prognosis. Data from major PAH clinical trials indicate that nearly 78.4% of participants are women. According to the REVEAL registry, the most common causes of PAH in women are connective tissue disease-associated PAH (CTD-PAH), idiopathic PAH (IPAH), and congenital heart disease-associated PAH (CHD-PAH). Women are often found to have better baseline right ventricular (RV) function and hemodynamics before treatment, as well as more favorable RV adaptation post-therapy. They also demonstrate a stronger response to endothelin receptor antagonists (ERA) and prostacyclins. Most notably, these factors contribute to better survival outcomes in women compared to men. In conclusion, significant sex-based differences exist in PAH, underscoring the need for personalized treatment approaches that consider sex-related factors. Future research should focus on optimizing therapeutic strategies to improve outcomes for both sexes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lung Health Department, Organ Transplant Center, King Faisal Specialist Hospital and Research Centre, Almaather, Riyadh 12713, Saudi Arabia.
- Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy.
- Department of Translational Medical Sciences, Federico II University, Naples, Italy.
ORCID-Profile: Noura Alturaif
Zitieren
APA
Alturaif, N., Attanasio, U., & Mercurio, V. (2025). Pulmonary arterial hypertension: sex-specific differences and outcomes. Therapeutic Advances in Respiratory Disease, 19. https://doi.org/10.1177/17534666251350493
Vancouver
Alturaif N, Attanasio U, Mercurio V. Pulmonary arterial hypertension: sex-specific differences and outcomes. Therapeutic Advances in Respiratory Disease. 2025;19. doi:10.1177/17534666251350493
BibTeX
@article{Alturaif2025,
author = {Alturaif, Noura and Attanasio, Umberto and Mercurio, Valentina},
title = {Pulmonary arterial hypertension: sex-specific differences and outcomes},
journal = {Therapeutic Advances in Respiratory Disease},
year = {2025},
volume = {19},
doi = {10.1177/17534666251350493}
}
EUVIMED